Provider: NIHR Journals Library
Content:text/plain; charset="UTF-8"
TY - ELEC
LB - 1.
AU - Harnan, SE
AU - Woods, B
AU - Schmitt, L
AU - Kearns, B
AU - Srivastava, T
AU - Scope, A
TI - Protocol for the technology evaluation of cefiderocol for treating severe aerobic Gram-negative bacterial infections
J2 - Health Technol Assess
PY - 2021
ER -
TY - JOUR
LB - 2.
AU - Hawkey, PM
AU - Warren, RE
AU - Livermore, DM
AU - McNulty, CA
AU - Enoch, DA
AU - Otter, JA
TI - Treatment of infections caused by multidrug-resistant gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party
J2 - J Antimicrob Chemother
SP - iii2
PY - 2018
VL - 73
SP - iii2
ER -
TY - JOUR
LB - 3.
AU - Munita, JM
AU - Arias, CA
TI - Mechanisms of antibiotic resistance
J2 - Microbiol Spectr
SP - 1
PY - 2016
VL - 4
SP - 1
ER -
TY - JOUR
LB - 4.
AU - Hawkey, PM
TI - Multidrug-resistant Gram-negative bacteria: a product of globalization
J2 - J Hosp Infect
SP - 241
PY - 2015
VL - 89
SP - 241
ER -
TY - JOUR
LB - 5.
AU - McNulty, CAM
AU - Boyle, P
AU - Nichols, T
AU - Clappison, P
AU - Davey, P
TI - Don’t wear me out – the public’s knowledge of and attitudes to antibiotic use
J2 - J Antimicrob Chemother
SP - 727
PY - 2007
VL - 59
SP - 727
ER -
TY - BOOK
LB - 6.
AU - Public Health England
J2 - English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Report 2019 to 2020
PY - 2020
ER -
TY - JOUR
LB - 7.
AU - Hughes, S
AU - Gilchrist, M
AU - Heard, K
AU - Hamilton, R
AU - Sneddon, J
TI - Treating infections caused by carbapenemase-producing Enterobacterales (CPE): a pragmatic approach to antimicrobial stewardship on behalf of the UKCPA Pharmacy Infection Network (PIN)
J2 - JAC-Antimicrob Resist
SP - dlaa075
PY - 2020
VL - 2
SP - dlaa075
ER -
TY - GEN
LB - 8.
AU - World Health Organization
J2 - WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed
PY - 2017
ER -
TY - GEN
LB - 9.
AU - World Health Organization
J2 - Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics
PY - 2017
ER -
TY - JOUR
LB - 10.
AU - Tan, X
AU - Kim, HS
AU - Baugh, K
AU - Huang, Y
AU - Kadiyala, N
AU - Wences, M
TI - Therapeutic options for metallo-β-lactamase-producing Enterobacterales
J2 - Infect Drug Resist
SP - 125
PY - 2021
VL - 14
SP - 125
ER -
TY - JOUR
LB - 11.
AU - Ito, A
AU - Kohira, N
AU - Bouchillon, SK
AU - West, J
AU - Rittenhouse, S
AU - Sader, HS
TI - In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria
J2 - J Antimicrob Chemother
SP - 670
PY - 2016
VL - 71
SP - 670
ER -
TY - JOUR
LB - 12.
AU - Ito, A
AU - Nishikawa, T
AU - Matsumoto, S
AU - Yoshizawa, H
AU - Sato, T
AU - Nakamura, R
TI - Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa
J2 - Antimicrob Agents Chemother
SP - 7396
PY - 2016
VL - 60
SP - 7396
ER -
TY - JOUR
LB - 13.
AU - Portsmouth, S
AU - van Veenhuyzen, D
AU - Echols, R
AU - Machida, M
AU - Ferreira, JCA
AU - Ariyasu, M
TI - Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
J2 - Lancet Infect Dis
SP - 1319
PY - 2018
VL - 18
SP - 1319
ER -
TY - JOUR
LB - 14.
AU - Wunderink, RG
AU - Matsunaga, Y
AU - Ariyasu, M
AU - Clevenbergh, P
AU - Echols, R
AU - Kaye, KS
TI - Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
J2 - Lancet Infect Dis
SP - 213
PY - 2021
VL - 21
SP - 213
ER -
TY - JOUR
LB - 15.
AU - Bassetti, M
AU - Echols, R
AU - Matsunaga, Y
AU - Ariyasu, M
AU - Doi, Y
AU - Ferrer, R
TI - Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
J2 - Lancet Infect Dis
SP - 226
PY - 2021
VL - 21
SP - 226
ER -
TY - BOOK
LB - 16.
AU - Tsuji, M
AU - Hackel, M
AU - Echols, R
AU - Yamano, Y
AU - Sahm, DF
J2 - In Vitro Activity of Cefiderocol Against Globally Collected Carbapenem-Resistant Gram-Negative Bacteria Isolated from Urinary Tract Source: SIDERO-CR-2014/2016
PY - 2017
ER -
TY - BOOK
LB - 17.
AU - Nguyen, S
J2 - In Vitro Antibacterial Activity of Cefiderocol against a Multi-National Collection of Carbapenem Non-Susceptible Gram-Negative Bacteria Isolated from Respiratory, Blood, Skin/Soft Tissue and Urinary Sources of Infection: SIDERO-WT-2014-2017
PY - 2017
ER -
TY - JOUR
LB - 18.
AU - Zhanel, GG
AU - Golden, AR
AU - Zelenitsky, S
AU - Wiebe, K
AU - Lawrence, CK
AU - Adam, HJ
TI - Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli
J2 - Drugs
SP - 271
PY - 2019
VL - 79
SP - 271
ER -
TY - ELEC
LB - 19.
AU - Shionogi
J2 - European Medicines Agency. Annex I: Summary of Product Characteristics Fetcroja 1g
ER -
TY - GEN
LB - 20.
AU - National Institute for Health and Care Excellence
J2 - Cefiderocol for Treating Severe Drug-Resistant Gram-Negative Bacterial Infections
ER -
TY - BOOK
LB - 21.
AU - Rothery, C
AU - Woods, B
AU - Schmitt, L
AU - Claxton, K
AU - Palmer, S
AU - Sculpher, M
J2 - Framework for Value Assessment of New Pharmaceuticals: Implications of Alternative Funding Arrangements for NICE Appraisal
PY - 2018
ER -
TY - GEN
LB - 22.
AU - Public Health England
J2 - Framework of Actions to Contain Carbapenemase-Producing Enterobacterales
PY - 2020
ER -
TY - GEN
LB - 23.
AU - Public Health England
J2 - UK Standards for Microbiology Investigations: Detection of Bacteria with Carbapenem-hydrolysing β-lactamases (Carbapenemases)
PY - 2020
ER -
TY - ELEC
LB - 24.
AU - European Committee on Antimicrobial Susceptibility Testing
J2 - Standard Operating Procedure: Setting Breakpoints for New Antimicrobial Agents
PY - 2019
ER -
TY - JOUR
LB - 25.
AU - Harnan, SE
AU - Cooper, K
AU - Jones, SL
AU - Jones, E
TI - Pruning and prioritising: a case study of a pragmatic method for managing a rapid systematic review with limited resources
J2 - Evid Policy J Res Debate Pract
SP - 589
PY - 2015
VL - 11
SP - 589
ER -
TY - JOUR
LB - 26.
AU - Uttley, L
AU - Whiteman, BL
AU - Woods, HB
AU - Harnan, S
AU - Philips, ST
AU - Cree, IA
AU - Early Cancer Detection Consortium
TI - Building the evidence base of blood-based biomarkers for early detection of cancer: a rapid systematic mapping review
J2 - EBioMedicine
SP - 164
PY - 2016
VL - 10
SP - 164
ER -
TY - BOOK
LB - 27.
AU - Kaltenthaler, E
AU - Tappenden, P
AU - Paisley, S
AU - Squires, H
J2 - NICE DSU Technical Support Document 13: Identifying and Reviewing Evidence to Inform the Conceptualisation and Population of Cost-Effectiveness Models
PY - 2011
ER -
TY - JOUR
LB - 28.
AU - Hoy, D
AU - Brooks, P
AU - Woolf, A
AU - Blyth, F
AU - March, L
AU - Bain, C
TI - Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement
J2 - J Clin Epidemiol
SP - 934
PY - 2012
VL - 65
SP - 934
ER -
TY - BOOK
LB - 29.
AU - Munn, Z
AU - Moola, S
AU - Lisy, K
AU - Riitano, D
AU - Tufanaru, C
AU - Aromataris, E
AU - Lockwood, C
AU - Porritt, K
AU - Pilla, B
AU - Jordan, Z
TI - Chapter 5: Systematic reviews of prevalence and incidence
J2 - JBI Manual for Evidence Synthesis
PY - 2024
ER -
TY - JOUR
LB - 30.
AU - Hinneburg, I
TI - ROBINS-1: a tool for assessing risk of bias in non-randomised studies of interventions
J2 - Med Monatsschr Pharm
SP - 175
PY - 2017
VL - 40
SP - 175
ER -
TY - JOUR
LB - 31.
AU - Sterne, JA
AU - Savović, J
AU - Page, MJ
AU - Elbers, RG
AU - Blencowe, NS
AU - Boutron, I
TI - RoB 2: a revised tool for assessing risk of bias in randomised trials
J2 - BMJ
SP - l4898
PY - 2019
VL - 366
SP - l4898
ER -
TY - BOOK
LB - 32.
AU - Peterson, J
AU - Welch, V
AU - Losos, M
AU - Tugwell, P
J2 - The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses
PY - 2011
ER -
TY - other
LB - 33.
AU - Shionogi
J2 - Candor Simulation – Retrospective Analysis of Cefiderocol and Comparators by Population PK/PD Simulation
PY - 2021
ER -
TY - ELEC
LB - 34.
AU - Shionogi
J2 - Response to EEPRU’s Data Request Relating to SIDERO-WT
PY - 2021
ER -
TY - ELEC
LB - 35.
AU - Shionogi
J2 - Response to EEPRU’s Data Request Relating to SIDERO-CR
PY - 2021
ER -
TY - JOUR
LB - 36.
AU - Albano, M
AU - Karau, MJ
AU - Schuetz, AN
AU - Patel, R
TI - Comparison of agar dilution to broth microdilution for testing in vitro activity of cefiderocol against Gram-negative Bacilli
J2 - J Clin Microbiol
SP - 17
PY - 2020
VL - 59
SP - 17
ER -
TY - JOUR
LB - 37.
AU - Biagi, M
AU - Vialichka, A
AU - Jurkovic, M
AU - Wu, T
AU - Shajee, A
AU - Lee, M
TI - Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin B, or trimethoprim-sulfamethoxazole against multidrug-resistant Stenotrophomonas maltophilia
J2 - Antimicrob Agents Chemother
SP - e00559-20
PY - 2020
VL - 64
SP - e00559-20
ER -
TY - JOUR
LB - 38.
AU - Delgado-Valverde, M
AU - Del Carmen Conejo, M
AU - Serrano, L
AU - Fernandez-Cuenca, F
AU - Pascual, A
TI - Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia
J2 - J Antimicrob Chemother
SP - 1840
PY - 2020
VL - 75
SP - 1840
ER -
TY - JOUR
LB - 39.
AU - Ghazi, IM
AU - Monogue, ML
AU - Tsuji, M
AU - Nicolau, DP
TI - Humanized exposures of cefiderocol, a siderophore cephalosporin, display sustained in vivo activity against siderophore-resistant Pseudomonas aeruginosa
J2 - Pharmacology
SP - 278
PY - 2018
VL - 101
SP - 278
ER -
TY - JOUR
LB - 40.
AU - Ghazi, IM
AU - Monogue, ML
AU - Tsuji, M
AU - Nicolau, DP
TI - Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model
J2 - Int J Antimicrob Agents
SP - 206
PY - 2018
VL - 51
SP - 206
ER -
TY - JOUR
LB - 41.
AU - Golden, AR
AU - Adam, HJ
AU - Baxter, M
AU - Walkty, A
AU - Lagace-Wiens, P
AU - Karlowsky, JA
AU - Zhanel, GG
TI - In vitro activity of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacilli isolated from patients in Canadian Intensive Care Units
J2 - Diagn Microbiol Infect Dis
SP - 115012
PY - 2020
VL - 97
SP - 115012
ER -
TY - JOUR
LB - 42.
AU - Hackel, MA
AU - Tsuji, M
AU - Yamano, Y
AU - Echols, R
AU - Karlowsky, JA
AU - Sahm, DF
TI - In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016
J2 - Antimicrob Agents Chemother
SP - e01968
PY - 2018
VL - 62
SP - e01968
ER -
TY - JOUR
LB - 43.
AU - Hackel, MA
AU - Tsuji, M
AU - Yamano, Y
AU - Echols, R
AU - Karlowsky, JA
AU - Sahm, DF
TI - Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth
J2 - Diagn Microbiol Infect Dis
SP - 321
PY - 2019
VL - 94
SP - 321
ER -
TY - JOUR
LB - 44.
AU - Hackel, MA
AU - Tsuji, M
AU - Yamano, Y
AU - Echols, R
AU - Karlowsky, JA
AU - Sahma, DF
TI - In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative Bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 study)
J2 - Antimicrob Agents Chemother
SP - e00093-17
PY - 2017
VL - 61
SP - e00093-17
ER -
TY - JOUR
LB - 45.
AU - Hsueh, SC
AU - Lee, YJ
AU - Huang, YT
AU - Liao, CH
AU - Tsuji, M
AU - Hsueh, PR
TI - In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan
J2 - J Antimicrob Chemother
SP - 380
PY - 2019
VL - 74
SP - 380
ER -
TY - JOUR
LB - 46.
AU - Huband, MD
AU - Ito, A
AU - Tsuji, M
AU - Sader, HS
AU - Fedler, KA
AU - Flamm, RK
TI - Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design
J2 - Diagn Microbiol Infect Dis
SP - 198
PY - 2017
VL - 88
SP - 198
ER -
TY - JOUR
LB - 47.
AU - Iregui, A
AU - Khan, Z
AU - Landman, D
AU - Quale, J
TI - Activity of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii endemic to medical centers in New York City
J2 - Microb Drug Resist
SP - 722
PY - 2020
VL - 26
SP - 722
ER -
TY - JOUR
LB - 48.
AU - Ito, A
AU - Nishikawa, T
AU - Ota, M
AU - Ito-Horiyama, T
AU - Ishibashi, N
AU - Sato, T
TI - Stability and low induction propensity of cefiderocol against chromosomal AmpC b-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae
J2 - J Antimicrob Chemother
SP - 3049
PY - 2018
VL - 73
SP - 3049
ER -
TY - JOUR
LB - 49.
AU - Johnston, BD
AU - Thuras, P
AU - Porter, SB
AU - Clabots, C
AU - Johnsona, JR
TI - Activity of cefiderocol, ceftazidime-avibactam, and eravacycline against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-20017) in relation to phylogenetic background, sequence type 131 subclones, blaCTX-M genotype, and coresistance
J2 - Diagn Microbiol Infect Dis
SP - 115314
PY - 2021
VL - 100
SP - 115314
ER -
TY - JOUR
LB - 50.
AU - Karlowsky, JA
AU - Hackel, MA
AU - Tsuji, M
AU - Yamano, Y
AU - Echols, R
AU - Sahm, DF
TI - In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative Bacilli isolated by clinical laboratories in North America and Europe in 2015–2016: SIDERO-WT-2015
J2 - Int J Antimicrob Agents
SP - 456
PY - 2019
VL - 53
SP - 456
ER -
TY - JOUR
LB - 51.
AU - Katsube, T
AU - Echols, R
AU - Arjona Ferreira, JC
AU - Krenz, HK
AU - Berg, JK
AU - Galloway, C
TI - Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment
J2 - J Clin Pharmacol
SP - 584
PY - 2017
VL - 57
SP - 584
ER -
TY - JOUR
LB - 52.
AU - Katsube, T
AU - Echols, R
AU - Wajima, T
TI - Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin
J2 - Clin Infect Dis
SP - S552
PY - 2019
VL - 69
SP - S552
ER -
TY - JOUR
LB - 53.
AU - Katsube, T
AU - Saisho, Y
AU - Shimada, J
AU - Furuie, H
TI - Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects
J2 - J Antimicrob Chemother
SP - 1971
PY - 2019
VL - 74
SP - 1971
ER -
TY - JOUR
LB - 54.
AU - Kawaguchi, N
AU - Katsube, T
AU - Echols, R
AU - Wajima, T
TI - Population pharmacokinetic analysis of cefiderocol, a parenteral siderophore cephalosporin, in healthy subjects, subjects with various degrees of renal function, and patients with complicated urinary tract infection or acute uncomplicated pyelonephritis
J2 - Antimicrob Agents Chemother
SP - e01391-17
PY - 2018
VL - 62
SP - e01391-17
ER -
TY - JOUR
LB - 55.
AU - Kawaguchi, N
AU - Katsube, T
AU - Echols, R
AU - Wajima, T
TI - Population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia, bloodstream infection/sepsis, or complicated urinary tract infection
J2 - Antimicrob Agents Chemother
SP - 17
PY - 2021
VL - 65
SP - 17
ER -
TY - JOUR
LB - 56.
AU - Kawai, A
AU - McElheny, CL
AU - Iovleva, A
AU - Kline, EG
AU - Sluis-Cremer, N
AU - Shields, RK
AU - Doi, Y
TI - Structural basis of reduced susceptibility to ceftazidime-avibactam and cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion
J2 - Antimicrob Agents Chemother
SP - e00198-20
PY - 2020
VL - 64
SP - e00198-20
ER -
TY - JOUR
LB - 57.
AU - Matsumoto, S
AU - Singley, CM
AU - Hoover, J
AU - Nakamura, R
AU - Echols, R
AU - Rittenhouse, S
TI - Efficacy of cefiderocol against carbapenem-resistant Gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics
J2 - Antimicrob Agents Chemother
SP - e00700-17
PY - 2017
VL - 61
SP - e00700-17
ER -
TY - JOUR
LB - 58.
AU - Nath, S
AU - Moussavi, F
AU - Abraham, D
AU - Landman, D
AU - Quale, J
TI - In vitro and in vivo activity of single and dual antimicrobial agents against KPC-producing Klebsiella pneumoniae
J2 - J Antimicrob Chemother
SP - 431
PY - 2018
VL - 73
SP - 431
ER -
TY - JOUR
LB - 59.
AU - Paul Morris, C
AU - Bergman, Y
AU - Tekle, T
AU - Fissel, JA
AU - Tamma, PD
AU - Simner, PJ
TI - Cefiderocol antimicrobial susceptibility testing against multidrug-resistant Gram-negative bacilli: a comparison of disk diffusion to broth microdilution
J2 - J Clin Microbiol
SP - e01649-20
PY - 2021
VL - 59
SP - e01649-20
ER -
TY - JOUR
LB - 60.
AU - Pybus, CA
AU - Felder-Scott, C
AU - Obuekwe, V
AU - Greenberg, DE
TI - Cefiderocol retains antibiofilm activity in multidrug-resistant Gram-negative pathogens
J2 - Antimicrob Agents Chemother
SP - e01194-20
PY - 2021
VL - 65
SP - e01194-20
ER -
TY - JOUR
LB - 61.
AU - Pybus, CA
AU - Greenberg, DE
TI - Cefiderocol retains anti-biofilm activity in MDR Gram-negative pathogens
J2 - Open Forum Infect
SP - S323
PY - 2019
VL - 6
SP - S323
ER -
TY - JOUR
LB - 62.
AU - Rolston, KVI
AU - Gerges, B
AU - Shelburne, S
AU - Aitken, SL
AU - Raad, I
AU - Prince, RA
TI - Activity of cefiderocol and comparators against isolates from cancer patients
J2 - Antimicrob Agents Chemother
SP - e01955-19
PY - 2020
VL - 64
SP - e01955-19
ER -
TY - JOUR
LB - 63.
AU - Sanabria, C
AU - Migoya, E
AU - Mason, JW
AU - Stanworth, SH
AU - Katsube, T
AU - Machida, M
TI - Effect of cefiderocol, a siderophore cephalosporin, on QT/QTc interval in healthy adult subjects
J2 - Clin Ther
SP - 1724
PY - 2019
VL - 41
SP - 1724
ER -
TY - JOUR
LB - 64.
AU - Sato, T
AU - Ito, A
AU - Ishioka, Y
AU - Matsumoto, S
AU - Rokushima, M
AU - Kazmierczak, KM
TI - Escherichia coli strains possessing a four amino acid YRIN insertion in PBP3 identified as part of the SIDERO-WT-2014 surveillance study
J2 - JAC-Antimicrob Resist
SP - dlaa081
PY - 2020
VL - 2
SP - dlaa081
ER -
TY - JOUR
LB - 65.
AU - Talan, DA
AU - Takhar, SS
AU - Krishnadasan, A
AU - Mower, WR
AU - Pallin, DJ
AU - Garg, M
TI - Emergence of extended-spectrum beta-lactamase urinary tract infections among hospitalized emergency department patients in the United States
J2 - Ann Emerg Med
SP - 32
PY - 2021
VL - 77
SP - 32
ER -
TY - JOUR
LB - 66.
AU - Tsiplakou, S
AU - Papaioannou, V
AU - Trikka-Graphakos, E
AU - Charalampakis, N
AU - Sereti, C
AU - Lebessi, E
TI - Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals
J2 - J Antimicrob Chemother
SP - 1704
PY - 2017
VL - 72
SP - 1704
ER -
TY - JOUR
LB - 67.
AU - Dobias, J
AU - Denervaud-Tendon, V
AU - Poirel, L
AU - Nordmann, P
TI - Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens
J2 - Eur J Clin Microbiol Infect Dis
SP - 2319
PY - 2017
VL - 36
SP - 2319
ER -
TY - JOUR
LB - 68.
AU - Jacobs, MR
AU - Abdelhamed, AM
AU - Good, CE
AU - Rhoads, DD
AU - Hujer, KM
AU - Hujer, AM
TI - ARGONAUT-I: Activity of cefiderocol (s-649266), a siderophore cephalosporin, against Gram-negative bacteria, including carbapenem-resistant nonfermenters and Enterobacteriaceae with defined extended-spectrum beta-lactamases and carbapenemases
J2 - Antimicrob Agents Chemother
SP - e01801-18
PY - 2019
VL - 63
SP - e01801-18
ER -
TY - JOUR
LB - 69.
AU - Mushtaq, S
AU - Sadouki, Z
AU - Vickers, A
AU - Livermore, DM
AU - Woodford, N
TI - In vitro activity of cefiderocol, a siderophore cephalosporin, against multidrug-resistant Gram-negative bacteria
J2 - Antimicrob Agents Chemother
SP - e01582-20
PY - 2020
VL - 64
SP - e01582-20
ER -
TY - JOUR
LB - 70.
AU - Ito, A
AU - Sato, T
AU - Ota, M
AU - Takemura, M
AU - Nishikawa, T
AU - Toba, S
TI - In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria
J2 - Antimicrob Agents Chemother
SP - e01454-17
PY - 2018
VL - 62
SP - e01454-17
ER -
TY - JOUR
LB - 71.
AU - Kresken, M
AU - Korte-Berwanger, M
AU - Gatermann, SG
AU - Pfeifer, Y
AU - Pfennigwerth, N
AU - Seifert, H
AU - Werner, G
TI - In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany
J2 - Int J Antimicrob Agents
SP - 106128
PY - 2020
VL - 56
SP - 106128
ER -
TY - JOUR
LB - 72.
AU - Bleibtreu, A
AU - Dortet, L
AU - Bonnin, RA
AU - Wyplosz, B
AU - Sacleux, SC
AU - Mihaila, L
TI - Susceptibility testing is key for the success of cefiderocol treatment: a retrospective Cohort study
J2 - Microorganisms
SP - 282
PY - 2021
VL - 9
SP - 282
ER -
TY - JOUR
LB - 73.
AU - Falcone, M
AU - Tiseo, G
AU - Nicastro, M
AU - Leonildi, A
AU - Vecchione, A
AU - Casella, C
TI - Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in ICU patients
J2 - Clin Infect Dis
SP - 2021
PY - 2020
VL - 17
SP - 2021
ER -
TY - JOUR
LB - 74.
AU - Haller, S
AU - Kramer, R
AU - Becker, K
AU - Bohnert, JA
AU - Eckmanns, T
AU - Hans, JB
TI - Extensively drug-resistant Klebsiella pneumoniae ST307 outbreak, north-eastern Germany, June to October 2019
J2 - Euro Surveill
SP - 1900734
PY - 2019
VL - 24
SP - 1900734
ER -
TY - JOUR
LB - 75.
AU - Oliva, A
AU - Ceccarelli, G
AU - De Angelis, M
AU - Sacco, F
AU - Miele, MC
AU - Mastroianni, CM
AU - Venditti, M
TI - Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii
J2 - J Glob Antimicrob Resist
SP - 292
PY - 2020
VL - 23
SP - 292
ER -
TY - JOUR
LB - 76.
AU - Shields, RK
AU - Iovleva, A
AU - Kline, EG
AU - Kawai, A
AU - McElheny, CL
AU - Doi, Y
TI - Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in Enterobacter cloacae complex following exposure to cefepime
J2 - Clin Infect Dis
SP - 2713
PY - 2020
VL - 71
SP - 2713
ER -
TY - JOUR
LB - 77.
AU - Zingg, S
AU - Nicoletti, GJ
AU - Kuster, S
AU - Junker, M
AU - Widmer, A
AU - Egli, A
TI - Cefiderocol for extensively drug-resistant Gram-negative bacterial infections: real-world experience from a case series and review of the literature
J2 - Open Forum Infect
SP - ofaa185
PY - 2020
VL - 7
SP - ofaa185
ER -
TY - JOUR
LB - 78.
AU - Johnston, BD
AU - Thuras, P
AU - Porter, SB
AU - Anacker, M
AU - VonBank, B
AU - Vagnone, PS
TI - Activity of cefiderocol, ceftazidime-avibactam, and eravacycline against carbapenem-resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, coresistance, and region
J2 - Antimicrob Agents Chemother
SP - e00797-20
PY - 2020
VL - 64
SP - e00797-20
ER -
TY - JOUR
LB - 79.
AU - Kazmierczak, KM
AU - Tsuji, M
AU - Wise, MG
AU - Hackel, M
AU - Yamano, Y
AU - Echols, R
AU - Sahm, DF
TI - In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-beta-lactamase-producing isolates (SIDERO-WT-2014 Study)
J2 - Int J Antimicrob Agents
SP - 177
PY - 2019
VL - 53
SP - 177
ER -
TY - JOUR
LB - 80.
AU - Kohira, N
AU - West, J
AU - Ito, A
AU - Ito-Horiyama, T
AU - Nakamura, R
AU - Sato, T
TI - In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains
J2 - Antimicrob Agents Chemother
SP - 729
PY - 2016
VL - 60
SP - 729
ER -
TY - JOUR
LB - 81.
AU - Longshaw, C
AU - Manissero, D
AU - Tsuji, M
AU - Echols, R
AU - Yamano, Y
TI - In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe
J2 - JAC Antimicrob Resist
SP - dlaa060
PY - 2020
VL - 2
SP - dlaa060
ER -
TY - ELEC
LB - 82.
AU - Shionogi
J2 - National Institute of Health and Care Excellence, Antimicrobial Health Technology Evaluation: Cefiderocol for Treating Severe Aerobic Gram-Negative Bacterial Infections
ER -
TY - JOUR
LB - 83.
AU - Chakraborty, T
AU - Sadek, M
AU - Yao, Y
AU - Imirzalioglu, C
AU - Stephan, R
AU - Poirel, L
AU - Nordmann, P
TI - Cross-border emergence of Escherichia coli producing the carbapenemase NDM-5 in Switzerland and Germany
J2 - J Clin Microbiol
SP - e02238-20
PY - 2021
VL - 59
SP - e02238-20
ER -
TY - JOUR
LB - 84.
AU - Kaase, M
AU - Pfennigwerth, N
AU - Lange, F
AU - Anders, A
AU - Gatermann, SG
TI - Molecular epidemiology of VIM-1 producing Escherichia coli from Germany referred to the National Reference Laboratory
J2 - Int J Med Microbiol
SP - 784
PY - 2015
VL - 305
SP - 784
ER -
TY - JOUR
LB - 85.
AU - Livermore, DM
AU - Warner, M
AU - Mushtaq, S
AU - Doumith, M
AU - Zhang, J
AU - Woodford, N
TI - What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline
J2 - Int J Antimicrob Agents
SP - 415
PY - 2011
VL - 37
SP - 415
ER -
TY - JOUR
LB - 86.
AU - Ojdana, D
AU - Gutowska, A
AU - Sacha, P
AU - Majewski, P
AU - Wieczorek, P
AU - Tryniszewska, E
TI - Activity of ceftazidime-avibactam alone and in combination with ertapenem, fosfomycin, and tigecycline against carbapenemase-producing Klebsiella pneumoniae
J2 - Microb Drug Resist
SP - 1357
PY - 2019
VL - 25
SP - 1357
ER -
TY - JOUR
LB - 87.
AU - Perry, JD
AU - Naqvi, SH
AU - Mirza, IA
AU - Alizai, SA
AU - Hussain, A
AU - Ghirardi, S
TI - Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media
J2 - J Antimicrob Chemother
SP - 2288
PY - 2011
VL - 66
SP - 2288
ER -
TY - JOUR
LB - 88.
AU - Cuba, GT
AU - Rocha-Santos, G
AU - Cayô, R
AU - Streling, AP
AU - Nodari, CS
AU - Gales, AC
TI - In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa
J2 - J Antimicrob Chemother
SP - 1874
PY - 2020
VL - 75
SP - 1874
ER -
TY - JOUR
LB - 89.
AU - Aires, CA
AU - Pereira, PS
AU - de Araujo, CF
AU - Chagas, TP
AU - Oliveira, JC
AU - Buonora, SN
TI - Multiclonal expansion of Klebsiella pneumoniae isolates producing NDM-1 in Rio de Janeiro, Brazil
J2 - Antimicrob Agents Chemother
SP - e01048-16
PY - 2017
VL - 61
SP - e01048-16
ER -
TY - JOUR
LB - 90.
AU - Sonnevend, A
AU - Ghazawi, A
AU - Darwish, D
AU - Barathan, G
AU - Hashmey, R
AU - Ashraf, T
TI - In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula
J2 - Int J Infect Dis
SP - 253
PY - 2020
VL - 99
SP - 253
ER -
TY - JOUR
LB - 91.
AU - Vasoo, S
AU - Cunningham, SA
AU - Cole, NC
AU - Kohner, PC
AU - Menon, SR
AU - Krause, KM
TI - In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing Gram-negative Bacilli
J2 - Antimicrob Agents Chemother
SP - 7842
PY - 2015
VL - 59
SP - 7842
ER -
TY - JOUR
LB - 92.
AU - Jahan, S
AU - Davis, H
AU - Ashcraft, DS
AU - Pankey, GA
TI - Evaluation of the in vitro interaction of fosfomycin and meropenem against metallo-β-lactamase-producing Pseudomonas aeruginosa using Etest and time-kill assay
J2 - J Investig Med
SP - 371
PY - 2021
VL - 69
SP - 371
ER -
TY - GEN
LB - 93.
AU - Public Health England
J2 - English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Report 2018 to 2019
PY - 2020
ER -
TY - JOUR
LB - 94.
AU - Kohira, N
AU - Hackel, MA
AU - Ishioka, Y
AU - Kuroiwa, M
AU - Sahm, DF
AU - Sato, T
TI - Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)
J2 - J Glob Antimicrob Resist
SP - 738
PY - 2020
VL - 22
SP - 738
ER -
TY - ELEC
LB - 95.
AU - European Committee on Antimicrobial Susceptibility Testing
J2 - Breakpoint Tables for Interpretation of MICs and Zone Diameters
PY - 2021
ER -
TY - JOUR
LB - 96.
AU - Brown, DFJ
AU - Wootton, M
AU - Howe, RA
TI - Antimicrobial susceptibility testing breakpoints and methods from BSAC to EUCAST
J2 - J Antimicrob Chemother
SP - 3
PY - 2015
VL - 71
SP - 3
ER -
TY - BOOK
LB - 97.
AU - Dias, S
AU - Welton, NJ
AU - Sutton, AJ
AU - Ades, A
J2 - NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials
PY - 2014
ER -
TY - BOOK
LB - 98.
AU - Dias, S
AU - Welton, NJ
AU - Sutton, AJ
AU - Caldwell, DM
AU - Lu, G
AU - Ades, AE
J2 - NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials
PY - 2011
ER -
TY - BOOK
LB - 99.
AU - Daly, C
AU - Downing, BC
AU - Welton, NJ
J2 - A Practical Guide to Inconsistency Checks in Bayesian Network Meta-analysis
ER -
TY - report
LB - 100.
AU - EUnetHTA. Authoring Team
J2 - Cefiderocol (Fetcroja®) for the Treatment of Infections Due to Aerobic Gram-negative Organisms in Adults with Limited Treatment Options
SP - 122
PY - 2020
SP - 122
ER -
TY - JOUR
LB - 101.
AU - Bassetti, M
AU - Echols, R
AU - Matsunaga, Y
AU - Portsmouth, S
AU - Ariyasu, M
AU - Toyoizumi, K
TI - Efficacy and safety of cefiderocol and best available therapy in patients with serious infections caused by carbapenem-resistant Gram-negative infections: results of the pathogen-focused phase 3 CREDIBLE-CR study
J2 - Open Forum Infect
SP - S652
PY - 2020
VL - 7
SP - S652
ER -
TY - JOUR
LB - 102.
AU - Bassetti, M
AU - Ariyasu, M
AU - Binkowitz, B
AU - Nagata, TD
AU - Echols, RM
AU - Matsunaga, Y
TI - Designing a pathogen-focused study to address the high unmet medical need represented by carbapenem-resistant Gram-negative pathogens – the international, multicenter, randomized, open-label, phase 3 CREDIBLE-CR study
J2 - Infect Drug Resist
SP - 3607
PY - 2019
VL - 12
SP - 3607
ER -
TY - JOUR
LB - 103.
AU - Mushtaq, S
AU - Sadouki, Z
AU - Vickers, A
AU - Livermore, D
AU - Woodford, N
TI - In-vitro activity of cefiderocol against multidrug-resistant Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii isolates from the UK
J2 - Access Microbiology
SP - 50
PY - 2020
VL - 2
SP - 50
ER -
TY - conf
LB - 104.
AU - Mushtaq, S
AU - Sadouki, Z
AU - Vickers, A
AU - Livermore, DM
AU - Woodford, N
TI - In Vitro Activity of Cefiderocol against Extensively Drug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii from the UK
PY - 2019
ER -
TY - JOUR
LB - 105.
AU - Bojke, L
AU - Soares, M
AU - Claxton, K
AU - Colson, A
AU - Fox, A
AU - Jackson, C
TI - Developing a reference protocol for structured expert elicitation in health-care decision-making: a mixed-methods study
J2 - Health Technol Assess (Winchester, England)
SP - 1
PY - 2021
VL - 25
SP - 1
ER -
TY - ELEC
LB - 106.
AU - Chang, W
AU - Cheng, J
AU - Allaire, J
AU - Xie, Y
AU - McPherson, J
J2 - Package ‘Shiny’
PY - 2015
ER -
TY - BOOK
LB - 107.
AU - O’Hagan, A
AU - Buck, CE
AU - Daneshkhah, A
AU - Eiser, JR
AU - Garthwaite, PH
AU - Jenkinson, DJ
J2 - Uncertain Judgements: Eliciting Experts’ Probabilities
PY - 2006
ER -
TY - conf
LB - 108.
AU - Lopes, S
AU - Franceschini, M
AU - Han, Y
AU - Green, W
AU - Dymond, A
AU - Gill, A
TI - Economic Evaluation of Cefiderocol for the Treatment of Carbapenem Resistant Infections in the United States
PY - 2020
ER -
TY - JOUR
LB - 109.
AU - Tichy, E
AU - Torres, A
AU - Bassetti, M
AU - Kongnakorn, T
AU - Di Virgilio, R
AU - Irani, P
AU - Charbonneau, C
TI - Cost-effectiveness comparison of ceftazidime/avibactam versus meropenem in the empirical treatment of hospital-acquired pneumonia, including ventilator-associated pneumonia, in Italy
J2 - Clin Ther
SP - 802
PY - 2020
VL - 42
SP - 802
ER -
TY - JOUR
LB - 110.
AU - Kongnakorn, T
AU - Wagenlehner, F
AU - Falcone, M
AU - Tichy, E
AU - Di Virgilio, R
AU - Baillon-Plot, N
AU - Charbonneau, C
TI - Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections
J2 - Int J Antimicrob Agents
SP - 633
PY - 2019
VL - 54
SP - 633
ER -
TY - JOUR
LB - 111.
AU - Nguyen, CP
AU - Dan Do, TN
AU - Bruggemann, R
AU - Ten Oever, J
AU - Kolwijck, E
AU - Adang, EMM
AU - Wertheim, HF
TI - Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: a systematic review, meta-analysis, and cost-effectiveness analysis
J2 - Int J Antimicrob Agents
SP - 790
PY - 2019
VL - 54
SP - 790
ER -
TY - JOUR
LB - 112.
AU - Simon, MS
AU - Sfeir, MM
AU - Calfee, DP
AU - Satlin, MJ
TI - Cost-effectiveness of ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae bacteremia and pneumonia
J2 - Antimicrob Agents Chemother
SP - 23
PY - 2019
VL - 63
SP - 23
ER -
TY - JOUR
LB - 113.
AU - Chen, GJ
AU - Pan, SC
AU - Foo, J
AU - Morel, C
AU - Chen, WT
AU - Wang, JT
TI - Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: a cost-utility model focusing on Gram-negative bacteria
J2 - J Microbiol Immunol Infect
SP - 807
PY - 2019
VL - 52
SP - 807
ER -
TY - JOUR
LB - 114.
AU - Mewes, JC
AU - Pulia, MS
AU - Mansour, MK
AU - Broyles, MR
AU - Nguyen, HB
AU - Steuten, LM
TI - The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: a health economic model analysis
J2 - PLOS ONE
SP - e0214222
PY - 2019
VL - 14
SP - e0214222
ER -
TY - JOUR
LB - 115.
AU - Nelson, RE
AU - Ray, W
AU - Rubin, MA
AU - Schweizer, M
TI - Evaluating the Cost-effectiveness of Decolonization for Prevention of MRSA Infections using a Dynamic Transmission Model.
J2 - Antimicrobial Resistance and Infection Control Conference: 5th International Conference on Prevention and Infection Control, ICPIC
PY - 2019
VL - 8
ER -
TY - JOUR
LB - 116.
AU - Gordon, J
AU - Darlington, O
AU - McEwan, P
AU - Lumley, M
AU - Taie, A
AU - Hicks, M
TI - Estimating the value of new antimicrobials in the context of antimicrobial resistance: development and application of a dynamic disease transmission model
J2 - PharmacoEcon
SP - 857
PY - 2020
VL - 38
SP - 857
ER -
TY - JOUR
LB - 117.
AU - Wagner, AP
AU - Enne, VI
AU - Livermore, DM
AU - Craig, JV
AU - Turner, DA
AU - INHALE Study Group
TI - Review of health economic models exploring and evaluating treatment and management of hospital-acquired pneumonia and ventilator-associated pneumonia
J2 - J Hosp Infect
SP - 745
PY - 2020
VL - 106
SP - 745
ER -
TY - JOUR
LB - 118.
AU - Edwards, SJ
AU - Wordsworth, S
AU - Clarke, MJ
TI - Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam
J2 - Eur J Health Econ
SP - 181
PY - 2012
VL - 13
SP - 181
ER -
TY - JOUR
LB - 119.
AU - Grau, S
AU - Alvarez-lerma, F
AU - del Castillo, A
AU - Neipp, R
AU - Rubio-terrés, C
TI - Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain
J2 - J Chemother
SP - 203
PY - 2005
VL - 17
SP - 203
ER -
TY - JOUR
LB - 120.
AU - Kongnakorn, T
AU - Mwamburi, M
AU - Merchant, S
AU - Akhras, K
AU - Caro, JJ
AU - Nathwani, D
TI - Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation
J2 - Curr Med Res Opin
SP - 17
PY - 2010
VL - 26
SP - 17
ER -
TY - JOUR
LB - 121.
AU - Kauf, TL
AU - Prabhu, VS
AU - Medic, G
AU - Borse, RH
AU - Miller, B
AU - Gaultney, J
TI - Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections
J2 - BMC Infect Dis
SP - 314
PY - 2017
VL - 17
SP - 314
ER -
TY - BOOK
LB - 122.
AU - Schaffer, SK
AU - West, P
AU - Towse, A
AU - Henshall, C
AU - Mestre-Ferrandiz, J
AU - Masterton, R
J2 - Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions
PY - 2017
ER -
TY - ELEC
LB - 123.
AU - Medicines and Healthcare products Regulatory Agency
J2 - Aminoglycosides (Gentamicin, Amikacin, Tobramycin, and Neomycin): Increased Risk of Deafness in Patients with Mitochondrial Mutations
PY - 2021
ER -
TY - ELEC
LB - 124.
AU - Pfizer
J2 - National Institute of Health and Care Excellence, Antimicrobial Health Technology Evaluation: Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections
ER -
TY - JOUR
LB - 125.
AU - Tumbarello, M
AU - De Pascale, G
AU - Trecarichi, EM
AU - Spanu, T
AU - Antonicelli, F
AU - Maviglia, R
TI - Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients
J2 - Intensive Care Med
SP - 682
PY - 2013
VL - 39
SP - 682
ER -
TY - JOUR
LB - 126.
AU - Mushtaq, S
AU - Garello, P
AU - Vickers, A
AU - Woodford, N
AU - Livermore, DM
TI - Activity of cefepime/zidebactam (WCK 5222) against ‘problem’ antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory
J2 - J Antimicrob Chemother
SP - 1511
PY - 2021
VL - 76
SP - 1511
ER -
TY - JOUR
LB - 127.
AU - Livermore, DM
AU - Nicolau, DP
AU - Hopkins, KL
AU - Meunier, D
TI - Carbapenem-resistant Enterobacterales, carbapenem resistant organisms, carbapenemase-producing Enterobacterales, and carbapenemase-producing organisms: terminology past its ‘sell-by date’ in an era of new antibiotics and regional carbapenemase epidemiology
J2 - Clin Infect Dis
SP - 1776
PY - 2020
VL - 71
SP - 1776
ER -
TY - JOUR
LB - 128.
AU - Sisay, M
AU - Hagos, B
AU - Edessa, D
AU - Tadiwos, Y
AU - Mekuria, AN
TI - Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury
J2 - Pharmacol Res
SP - 105328
PY - 2021
VL - 163
SP - 105328
ER -
TY - JOUR
LB - 129.
AU - Chien, H-T
AU - Lin, Y-C
AU - Sheu, C-C
AU - Hsieh, K-P
AU - Chang, J-S
TI - Is colistin-associated acute kidney injury clinically important in adults? A systematic review and meta-analysis
J2 - Int J Antimicrob Agents
SP - 105889
PY - 2020
VL - 55
SP - 105889
ER -
TY - JOUR
LB - 130.
AU - Kerr, M
AU - Bedford, M
AU - Matthews, B
AU - O’Donoghue, D
TI - The economic impact of acute kidney injury in England
J2 - Nephrol Dial Transplant
SP - 1362
PY - 2014
VL - 29
SP - 1362
ER -
TY - JOUR
LB - 131.
AU - Wagenlehner, F
AU - Lucenteforte, E
AU - Pea, F
AU - Soriano, A
AU - Tavoschi, L
AU - Steele, VR
TI - Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins
J2 - Clin Microbiol Infect
SP - 671
PY - 2021
VL - 27
SP - 671
ER -
TY - JOUR
LB - 132.
AU - Oliota, AF
AU - Penteado, ST
AU - Tonin, FS
AU - Fernandez-Llimos, F
AU - Sanches, AC
TI - Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies
J2 - Diagn Microbiol Infect Dis
SP - 41
PY - 2019
VL - 94
SP - 41
ER -
TY - JOUR
LB - 133.
AU - Palacios-Baena, ZR
AU - Giannella, M
AU - Manissero, D
AU - Rodríguez-Baño, J
AU - Viale, P
AU - Lopes, S
TI - Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review
J2 - Clin Microbiol Infect
SP - 228
PY - 2020
VL - 27
SP - 228
ER -
TY - other
LB - 134.
AU - Open VIE Ltd. UK Draft Study Report. CARBAR
TI - A retrospective study to evaluate the epidemiology, standard of care, outcomes and resource use associated with patients who have or are at risk of, infection with carbapenem non-susceptible Gram-negative organisms of interest (Enterobacterales, Pseudomonas spp., Stenotrophomonas spp. and Acinetobacter spp.
PY - 2020
ER -
TY - JOUR
LB - 135.
AU - Merrick, B
AU - Tan, MKI
AU - Bisnauthsing, K
AU - Goldenberg, SD
TI - Healthcare resource use in hospitalized patients with carbapenem-resistant Gram-negative infections
J2 - J Hosp Infect
SP - 7
PY - 2021
VL - 110
SP - 7
ER -
TY - JOUR
LB - 136.
AU - Guyot, P
AU - Ades, A
AU - Ouwens, MJ
AU - Welton, NJ
TI - Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
J2 - BMC Med Res Methodol
SP - 1
PY - 2012
VL - 12
SP - 1
ER -
TY - BOOK
LB - 137.
AU - Latimer, N
J2 - NICE DSU Technical Support Document 14: Survival Analysis For Economic Evaluations Alongside Clinical Trials – Extrapolation With Patient-Level Data NICE Decision Support Unit
PY - 2011
ER -
TY - JOUR
LB - 138.
AU - Bucaloiu, ID
AU - Kirchner, HL
AU - Norfolk, ER
AU - Hartle, JE
AU - II,
AU - Perkins, RM
TI - Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury
J2 - Kidney Int
SP - 477
PY - 2012
VL - 81
SP - 477
ER -
TY - JOUR
LB - 139.
AU - Ara, R
AU - Brazier, JE
TI - Populating an economic model with health state utility values: moving toward better practice
J2 - Value Health
SP - 509
PY - 2010
VL - 13
SP - 509
ER -
TY - JOUR
LB - 140.
AU - Hadjiat, Y
AU - Serrie, A
AU - Treves, R
AU - Chomier, B
AU - Geranton, L
AU - Billon, S
TI - Pain associated with health and economic burden in France: results from recent National Health and Wellness Survey data
J2 - ClinicoEcon
SP - 53
PY - 2018
VL - 10
SP - 53
ER -
TY - JOUR
LB - 141.
AU - Wyld, M
AU - Morton, RL
AU - Hayen, A
AU - Howard, K
AU - Webster, AC
TI - A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments
J2 - PLOS Med
SP - e1001307
PY - 2012
VL - 9
SP - e1001307
ER -
TY - JOUR
LB - 142.
AU - Kerr, M
AU - Bray, B
AU - Medcalf, J
AU - O’Donoghue, DJ
AU - Matthews, B
TI - Estimating the financial cost of chronic kidney disease to the NHS in England
J2 - Nephrol Dial Transplant
SP - iii73
PY - 2012
VL - 27
SP - iii73
ER -
TY - JOUR
LB - 143.
AU - Muscedere, JG
AU - Shorr, AF
AU - Jiang, X
AU - Day, A
AU - Heyland, DK
TI - The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: an important determinant of outcome
J2 - J Crit Care
SP - 322.e7
PY - 2012
VL - 27
SP - 322.e7
ER -
TY - JOUR
LB - 144.
AU - Kolhe, NV
AU - Eldehni, MT
AU - Selby, NM
AU - McIntyre, CW
TI - The reimbursement and cost of acute kidney injury: a UK hospital perspective
J2 - Nephron Clin Pract
SP - 51
PY - 2014
VL - 126
SP - 51
ER -
TY - JOUR
LB - 145.
AU - Knight, GM
AU - Costelloe, C
AU - Deeny, SR
AU - Moore, LSP
AU - Hopkins, S
AU - Johnson, AP
TI - Quantifying where human acquisition of antibiotic resistance occurs: a mathematical modelling study
J2 - BMC Med
SP - 137
PY - 2018
VL - 16
SP - 137
ER -
TY - BOOK
LB - 146.
AU - Curtis, L
AU - Burns, A
J2 - Unit Costs of Health & Social Care
PY - 2020
ER -
TY - JOUR
LB - 147.
AU - Liangos, O
AU - Wald, R
AU - O’Bell, JW
AU - Price, L
AU - Pereira, BJ
AU - Jaber, BL
TI - Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey
J2 - Clin J Am Soc Nephrol
SP - 43
PY - 2006
VL - 1
SP - 43
ER -
TY - ELEC
LB - 148.
AU - Department of Health and Social Care
J2 - Drugs and Pharmaceutical Electronic Market Information Tool (eMIT)
PY - 2021
ER -
TY - ELEC
LB - 149.
AU - National Institute for Health and Care Excellence (NICE)
J2 - British National Formulary
PY - 2021
ER -
TY - other
LB - 150.
AU - World Health Organisation
J2 - WHO Collaboration Centre for Drug Statistics Methodology
PY - 2021
ER -
TY - JOUR
LB - 151.
AU - Kallel, H
AU - Hergafi, L
AU - Bahloul, M
AU - Hakim, A
AU - Dammak, H
AU - Chelly, H
TI - Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case–control study
J2 - Intensive Care Med
SP - 1162
PY - 2007
VL - 33
SP - 1162
ER -
TY - JOUR
LB - 152.
AU - Hawkey, PM
AU - Warren, RE
AU - Livermore, DM
AU - McNulty, CAM
AU - Enoch, DA
AU - Otter, JA
AU - Wilson, APR
TI - Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party
J2 - J Antimicrob Chemother
SP - iii2
PY - 2018
VL - 73
SP - iii2
ER -
TY - ELEC
LB - 153.
AU - Renascience Pharma Ltd
J2 - Renapime 1g Powder for Solution for Injection/Infusion: SmPC
ER -
TY - ELEC
LB - 154.
AU - National Institute for Health and Care Excellence (NICE)
J2 - BNF: British National Formulary – NICE 2021
PY - 2021
ER -
TY - BOOK
LB - 155.
AU - Department of Health and Social Care
J2 - Drugs and Pharmaceutical Electronic Market Information Tool (eMIT)
PY - 2021
ER -
TY - ELEC
LB - 156.
AU - National Institute for Health and Care Excellence
J2 - Antimicrobial Health Technology Evaluation: Ceftazidime with Avibactam for Treating Severe Aerobic Gram-negative Bacterial Infections: Final Scope London (National Institute for Health and Care Excellence)
PY - 2021
ER -
TY - GEN
LB - 157.
AU - Department of Health and Social Care
J2 - Impact Assessment 9553: 2018 Statutory Scheme – Branded Medicines Pricing
PY - 2018
ER -
TY - GEN
LB - 158.
AU - National Institute for Health and Care Excellence
J2 - Guide to the Methods of Technology Appraisal 2013
PY - 2013
ER -
TY - ELEC
LB - 159.
AU - EUCAST
J2 - New S, I and R Definitions
PY - 2021
ER -
TY - JOUR
LB - 160.
AU - Costelloe, C
AU - Metcalfe, C
AU - Lovering, A
AU - Mant, D
AU - Hay, AD
TI - Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis
J2 - BMJ
SP - c2096
PY - 2010
VL - 340
SP - c2096
ER -
TY - JOUR
LB - 161.
AU - Bell, BG
AU - Schellevis, F
AU - Stobberingh, E
AU - Goossens, H
AU - Pringle, M
TI - A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance
J2 - BMC Infect Dis
SP - 1
PY - 2014
VL - 14
SP - 1
ER -
TY - JOUR
LB - 162.
AU - Bakhit, M
AU - Hoffmann, T
AU - Scott, AM
AU - Beller, E
AU - Rathbone, J
AU - Del Mar, C
TI - Resistance decay in individuals after antibiotic exposure in primary care: a systematic review and meta-analysis
J2 - BMC Med
SP - 1
PY - 2018
VL - 16
SP - 1
ER -
TY - JOUR
LB - 163.
AU - Jeffrey, B
AU - Aanensen, DM
AU - Croucher, NJ
AU - Bhatt, S
TI - Predicting the future distribution of antibiotic resistance using time series forecasting and geospatial modelling
J2 - Wellcome Open Res
SP - 194
PY - 2020
VL - 5
SP - 194
ER -
TY - GEN
LB - 164.
AU - Organisation for Economic Co-operation and Development
J2 - Stemming the Superbug Tide: Just a Few Dollars More
ER -
TY - JOUR
LB - 165.
AU - Ortiz-Brizuela, E
AU - Caro-Vega, Y
AU - Bobadilla-del-Valle, M
AU - Leal-Vega, F
AU - Criollo-Mora, E
AU - Luis, BL
TI - The influence of hospital antimicrobial use on carbapenem-non-susceptible Enterobacterales incidence rates according to their mechanism of resistance: a time-series analysis
J2 - J Hosp Infect
SP - 757
PY - 2020
VL - 105
SP - 757
ER -
TY - JOUR
LB - 166.
AU - Gharbi, M
AU - Moore, LS
AU - Gilchrist, M
AU - Thomas, CP
AU - Bamford, K
AU - Brannigan, ET
AU - Holmes, AH
TI - Forecasting carbapenem resistance from antimicrobial consumption surveillance: lessons learnt from an OXA-48-producing Klebsiella pneumoniae outbreak in a West London renal unit
J2 - Int J Antimicrob Agents
SP - 150
PY - 2015
VL - 46
SP - 150
ER -
TY - JOUR
LB - 167.
AU - Berger, P
AU - Pascal, L
AU - Sartor, C
AU - Delorme, J
AU - Monge, P
AU - Ragon, CP
TI - Generalized additive model demonstrates fluoroquinolone use/resistance relationships for Staphylococcus aureus
J2 - Eur J Epidemiol
SP - 453
PY - 2004
VL - 19
SP - 453
ER -
TY - JOUR
LB - 168.
AU - McDonnell, L
AU - Armstrong, D
AU - Ashworth, M
AU - Dregan, A
AU - Malik, U
AU - White, P
TI - National disparities in the relationship between antimicrobial resistance and antimicrobial consumption in Europe: an observational study in 29 countries
J2 - J Antimicrob Chemother
SP - 3199
PY - 2017
VL - 72
SP - 3199
ER -
TY - JOUR
LB - 169.
AU - Pouwels, KB
AU - Freeman, R
AU - Muller-Pebody, B
AU - Rooney, G
AU - Henderson, KL
AU - Robotham, JV
AU - Smieszek, T
TI - Association between use of different antibiotics and trimethoprim resistance: going beyond the obvious crude association
J2 - J Antimicrob Chemother
SP - 1700
PY - 2018
VL - 73
SP - 1700
ER -
TY - JOUR
LB - 170.
AU - Colson, AR
AU - Megiddo, I
AU - Alvarez-Uria, G
AU - Gandra, S
AU - Bedford, T
AU - Morton, A
TI - Quantifying uncertainty about future antimicrobial resistance: comparing structured expert judgment and statistical forecasting methods
J2 - PLOS ONE
SP - e0219190
PY - 2019
VL - 14
SP - e0219190
ER -
TY - JOUR
LB - 171.
AU - Durham, L
AU - Ge, M
AU - Cuccia, A
AU - Quinn, J
TI - Modeling antibiotic resistance to project future rates: quinolone resistance in Escherichia coli
J2 - Eur J Clin Microbiol Infect Dis
SP - 353
PY - 2010
VL - 29
SP - 353
ER -
TY - JOUR
LB - 172.
AU - Goossens, H
AU - Ferech, M
AU - Vander Stichele, R
AU - Elseviers, M
AU - Group, EP
TI - Outpatient antibiotic use in Europe and association with resistance: a cross-national database study
J2 - Lancet
SP - 579
PY - 2005
VL - 365
SP - 579
ER -
TY - JOUR
LB - 173.
AU - Johnson, AP
AU - Muller-Pebody, B
AU - Budd, E
AU - Ashiru-Oredope, D
AU - Ladenheim, D
AU - Hain, D
TI - Improving feedback of surveillance data on antimicrobial consumption, resistance and stewardship in England: putting the data at your Fingertips
J2 - J Antimicrob Chemother
SP - 953
PY - 2017
VL - 72
SP - 953
ER -
TY - ELEC
LB - 174.
AU - European Centre for Disease Prevention and Control
J2 - European Surveillance of Antimicrobial Consumption Network (ESAC-Net)
PY - 2021
ER -
TY - ELEC
LB - 175.
AU - European Centre for Disease Prevention and Control
J2 - European Antimicrobial Resistance Surveillance Network (EARS-Net)
PY - 2021
ER -
TY - ELEC
LB - 176.
AU - European Centre for Disease Prevention and Control
J2 - Antimicrobial Resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2019
PY - 2020
ER -
TY - JOUR
LB - 177.
AU - Morel, CM
AU - Alm, RA
AU - Årdal, C
AU - Bandera, A
AU - Bruno, GM
AU - Carrara, E
TI - A one health framework to estimate the cost of antimicrobial resistance
J2 - Antimicrob Resist Infect Control
SP - 1
PY - 2020
VL - 9
SP - 1
ER -
TY - JOUR
LB - 178.
AU - Chatterjee, A
AU - Modarai, M
AU - Naylor, NR
AU - Boyd, SE
AU - Atun, R
AU - Barlow, J
TI - Quantifying drivers of antibiotic resistance in humans: a systematic review
J2 - Lancet Infect Dis
SP - e368
PY - 2018
VL - 18
SP - e368
ER -
TY - JOUR
LB - 179.
AU - Schuts, EC
AU - Boyd, A
AU - Muller, AE
AU - Mouton, JW
AU - Prins, JM
TI - The effect of antibiotic restriction programs on prevalence of antimicrobial resistance: a systematic review and meta-analysis
J2 - Open Forum Infect
SP - ofab070
PY - 2021
VL - 8
SP - ofab070
ER -
TY - JOUR
LB - 180.
AU - Holmes, AH
AU - Moore, LS
AU - Sundsfjord, A
AU - Steinbakk, M
AU - Regmi, S
AU - Karkey, A
TI - Understanding the mechanisms and drivers of antimicrobial resistance
J2 - Lancet
SP - 176
PY - 2016
VL - 387
SP - 176
ER -
TY - JOUR
LB - 181.
AU - Enne, VI
AU - Livermore, DM
AU - Stephens, P
AU - Hall, LM
TI - Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction
J2 - Lancet
SP - 1325
PY - 2001
VL - 357
SP - 1325
ER -
TY - JOUR
LB - 182.
AU - Nasrin, D
AU - Collignon, PJ
AU - Roberts, L
AU - Wilson, EJ
AU - Pilotto, LS
AU - Douglas, RM
TI - Effect of β lactam antibiotic use in children on pneumococcal resistance to penicillin: prospective cohort study
J2 - BMJ
SP - 28
PY - 2002
VL - 324
SP - 28
ER -
TY - BOOK
LB - 183.
AU - European Centre for Disease Prevention and Control
J2 - Point Prevalence Survey of Healthcare-Associated Infections and Antimicrobial Use in European Acute Care Hospitals
PY - 2013
ER -
TY - ELEC
LB - 184.
AU - National Institute for Health and Care Excellence
J2 - Pneumonia in Adults: Diagnosis and Management (CG.191)
PY - 2014
ER -
TY - GEN
LB - 185.
AU - Specialist Pharmacy Service (SPS)
J2 - Prescribing Outlook
PY - 2020
ER -
TY - JOUR
LB - 186.
AU - Castanheira, M
AU - Deshpande, LM
AU - Costello, A
AU - Davies, TA
AU - Jones, RN
TI - Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009–11 in 14 European and Mediterranean countries
J2 - J Antimicrob Chemother
SP - 1804
PY - 2014
VL - 69
SP - 1804
ER -
TY - ELEC
LB - 187.
AU - Public Health England
J2 - AMR Local Indicators
PY - 2021
ER -
TY - JOUR
LB - 188.
AU - Paul, M
AU - Carrara, E
AU - Retamar, P
AU - Tängdén, T
AU - Bitterman, R
AU - Bonomo, RA
TI - European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)
J2 - Clin Microbiol Infect
SP - 521
PY - 2022
VL - 28
SP - 521
ER -
TY - ELEC
LB - 189.
AU - Tamma, P
AU - Aitken, S
AU - Bonomo, R
AU - Mathers, A
AU - van Duin, D
AU - Clancy, C
J2 - Infectious Diseases Society of America Antimicrobial-resistant Treatment Guidance: Gram-Negative Bacterial Infections Infectious Diseases Society of America
PY - 2022
ER -
TY - JOUR
LB - 190.
AU - Walker, AS
AU - White, IR
AU - Turner, RM
AU - Hsu, LY
AU - Yeo, TW
AU - White, NJ
TI - Personalised randomised controlled trial designs – a new paradigm to define optimal treatments for carbapenem-resistant infections
J2 - Lancet Infect Dis
SP - e175
PY - 2021
VL - 21
SP - e175
ER -
TY - JOUR
LB - 191.
AU - Harnan, SE
AU - Tappenden, P
AU - Essat, M
AU - Gomersall, T
AU - Minton, J
AU - Wong, R
TI - Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath
J2 - Health Technol Assess
SP - 1
PY - 2015
VL - 19
SP - 1
ER -
TY - JOUR
LB - 192.
AU - Montori, VM
AU - Wilczynski, NL
AU - Morgan, D
AU - Haynes, RB
AU - Hedges, T
TI - Optimal search strategies for retrieving systematic reviews from Medline: analytical survey
J2 - BMJ
SP - 68
PY - 2005
VL - 330
SP - 68
ER -
TY - GEN
LB - 193.
AU - National Institute of Health and Care Excellence
J2 - Diabetic Foot Infection: Antimicrobial Prescribing. NICE Evidence Reviews Collection
PY - 2019
ER -
TY - JOUR
LB - 194.
AU - Li, L
AU - Smith, HE
AU - Atun, R
AU - Tudor Car, L
TI - Search strategies to identify observational studies in MEDLINE and Embase
J2 - Cochrane Database Syst Rev
SP - MR000041
PY - 2019
VL - 3
SP - MR000041
ER -
TY - JOUR
LB - 195.
AU - Ayiku, L
AU - Levay, P
AU - Hudson, T
AU - Craven, J
AU - Barrett, E
AU - Finnegan, A
AU - Adams, R
TI - The medline UK filter: development and validation of a geographic search filter to retrieve research about the UK from OVID medline
J2 - Health Info Libr J
SP - 200
PY - 2017
VL - 34
SP - 200
ER -
TY - JOUR
LB - 196.
AU - Ayiku, L
AU - Levay, P
AU - Hudson, T
AU - Craven, J
AU - Finnegan, A
AU - Adams, R
AU - Barrett, E
TI - The Embase UK filter: validation of a geographic search filter to retrieve research about the UK from OVID Embase
J2 - Health Info Libr J
SP - 121
PY - 2019
VL - 36
SP - 121
ER -
TY - JOUR
LB - 197.
AU - Bassetti, M
AU - Rello, J
AU - Blasi, F
AU - Goossens, H
AU - Sotgiu, G
AU - Tavoschi, L
TI - A systematic review on the impact of appropriate versus inappropriate initial antibiotic therapy on the outcomes of patients with severe bacterial infections
J2 - Int J Antimicrob Agents
SP - 106184
PY - 2020
VL - 56
SP - 106184
ER -
TY - JOUR
LB - 198.
AU - Arber, M
AU - Garcia, S
AU - Veale, T
AU - Edwards, M
AU - Shaw, A
AU - Glanville, JM
TI - Performance of Ovid Medline search filters to identify health state utility studies
J2 - Int J Technol Assess Health Care
SP - 472
PY - 2017
VL - 33
SP - 472
ER -
TY - JOUR
LB - 199.
AU - Katsube, T
AU - Wajima, T
AU - Ishibashi, T
AU - Arjona Ferreira, JC
AU - Echols, R
TI - Pharmacokinetic/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function
J2 - Antimicrob Agents Chemother
SP - e01381
PY - 2017
VL - 61
SP - e01381
ER -
TY - JOUR
LB - 200.
AU - Zasowski, EJ
AU - Bassetti, M
AU - Blasi, F
AU - Goossens, H
AU - Rello, J
AU - Sotgiu, G
TI - A systematic review of the effect of delayed appropriate antibiotic treatment on the outcomes of patients with severe bacterial infections
J2 - Chest
SP - 929
PY - 2020
VL - 158
SP - 929
ER -
TY - JOUR
LB - 201.
AU - Herkel, T
AU - Uvizl, R
AU - Doubravska, L
AU - Adamus, M
AU - Gabrhelik, T
AU - Htoutou Sedlakova, M
J2 - Epidemiology of Hospital-Acquired Pneumonia: Results of a Central European Multicenter, Prospective, Observational Study Compared with Data from the European Region
SP - 448
PY - 2016
VL - 160
SP - 448
ER -
TY - JOUR
LB - 202.
AU - Pena, C
AU - Gómez-Zorrilla, S
AU - Oriol, I
AU - Tubau, F
AU - Dominguez, M
AU - Pujol, M
TI - Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality
J2 - Eur J Clin Microbiol Infect Dis
SP - 413
PY - 2013
VL - 32
SP - 413
ER -
TY - JOUR
LB - 203.
AU - Amaral, AC
AU - Holder, MW
TI - Timing of antimicrobial therapy after identification of ventilator-associated condition is not associated with mortality in patients with ventilator-associated pneumonia: a cohort study
J2 - PLOS ONE
SP - e97575
PY - 2014
VL - 9
SP - e97575
ER -
TY - BOOK
LB - 204.
AU - Hyndman, RJ
AU - Athanasopoulos, G
J2 - Forecasting: Principles and Practice: OTexts
PY - 2018
ER -
TY - JOUR
LB - 205.
AU - Liboschik, T
AU - Fokianos, K
AU - Fried, R
TI - tscount: an R package for analysis of count time series following generalized linear models
J2 - J Stat Softw
SP - 1
PY - 2017
VL - 82
SP - 1
ER -
TY - JOUR
LB - 206.
AU - Aliabadi, S
AU - Anyanwu, P
AU - Beech, E
AU - Jauneikaite, E
AU - Wilson, P
AU - Hope, R
TI - Effect of antibiotic stewardship interventions in primary care on antimicrobial resistance of Escherichia coli bacteraemia in England (2013–18): a quasi-experimental, ecological, data linkage study
J2 - Lancet Infect Dis
SP - 1689
PY - 2021
VL - 21
SP - 1689
ER -
TY - JOUR
LB - 207.
AU - Kearns, B
AU - Stevenson, MD
AU - Triantafyllopoulos, K
AU - Manca, A
TI - Generalized linear models for flexible parametric modeling of the hazard function
J2 - Med Decis Making
SP - 867
PY - 2019
VL - 39
SP - 867
ER -
TY - BOOK
LB - 208.
AU - Public Health England
J2 - Escherichia coli (E. coli): Guidance, Data and Analysis
PY - 2017
ER -
TY - JOUR
LB - 209.
AU - Sharland, M
AU - Pulcini, C
AU - Harbarth, S
AU - Zeng, M
AU - Gandra, S
AU - Mathur, S
AU - Magrini, N
AU - 21st WHO Expert Committee on Selection and Use of Essential Medicines
TI - Classifying antibiotics in the WHO Essential Medicines List for optimal use – be AWaRe
J2 - Lancet Infect Dis
SP - 18
PY - 2018
VL - 18
SP - 18
ER -
TY - ELEC
LB - 210.
AU - Bennett Institute for Applied Data Science
J2 - OpenPrescribing.net
PY - 2021
ER -
TY - JOUR
LB - 211.
AU - Davey, P
AU - Brown, E
AU - Charani, E
AU - Fenelon, L
AU - Gould, IM
AU - Holmes, A
TI - Interventions to improve antibiotic prescribing practices for hospital inpatients
J2 - Cochrane Database Syst Rev
SP - CD003543
PY - 2013
SP - CD003543
ER -
TY - JOUR
LB - 212.
AU - Bhattacharya, A
AU - Hopkins, S
AU - Sallis, A
AU - Budd, EL
AU - Ashiru-Oredope, D
TI - A process evaluation of the UK-wide Antibiotic Guardian campaign: developing engagement on antimicrobial resistance
J2 - J Public Health
SP - e40
PY - 2017
VL - 39
SP - e40
ER -
TY - JOUR
LB - 213.
AU - McKenzie, E
AU - Gardner Jr, ES
TI - Damped trend exponential smoothing: a modelling viewpoint
J2 - Int J Forecast
SP - 661
PY - 2010
VL - 26
SP - 661
ER -
TY - JOUR
LB - 214.
AU - Spicknall, IH
AU - Foxman, B
AU - Marrs, CF
AU - Eisenberg, JN
TI - A modeling framework for the evolution and spread of antibiotic resistance: literature review and model categorization
J2 - Am J Epidemiol
SP - 508
PY - 2013
VL - 178
SP - 508
ER -